DLH to Announce First Quarter FY22 Financial Results
ATLANTA, Jan. 19, 2022 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading healthcare and...
Year: 2022
PepGen Appoints Laurie Keating as Chair of Board of Directors
Keating brings strong experience as a life science executive and Board memberBOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., a...
M Health Fairview University of Minnesota Medical Center Receives First Hyperfine Portable MRI to Grow its Advanced Imaging Systems Offering
World’s first FDA-cleared portable MRI expands leading neurosurgery suite’s tech capabilities for novel diagnostic and therapeutic approachesGUILFORD, Conn. and MINNEAPOLIS,...
SmileDirectClub Expands Oral Care Line With Launch Of Innovative New Fast-Dissolving Whitening Strips
Leading Oral Care Company Has Teamed with Peloton Star Tunde Oyeneyin to Promote the Power of a Bright and Healthy...
Recce Pharmaceuticals Announces Positive Safety Data from Second Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
Highlights: Seven subjects in cohort two intravenously dosed with RECCE® 327 (R327) at 150mg met all endpoints - indicating R327...
HCW Biologics’ Founder and CEO Dr. Hing C. Wong Participating in Cambridge Healthtech Institute’s Annual PepTalk Conference 2022
A Novel Platform to Create Multi-Functional Immunotherapeutics for Cancer Will Feature TOBI™ Discovery Platform and Lead Product Candidate, HCW9218MIRAMAR, Fla.,...
VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
Systemic bioavailability of JAK inhibitor (tofacitinib) and S1P receptor modulator (fingolimod) in topical formulation substantially lower compared to oral equivalents...
LifeMD Provides Initial FY2022 Guidance and Announces Preliminary FY2021 Revenues
Total FY2022 revenue anticipated to be in the range of $142 to $148 million Remains on track to achieve Adjusted...
X4 Pharmaceuticals to Present at B. Riley Securities Oncology Investor Conference
BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of...
ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles
100% of Patients On IMX-110 Completed Planned Treatment Cycles Immix Biopharma, Inc. (NASDAQ:IMMX) 100% of patients treated with IMX-110 completed...
InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector
CBT is the first of several rare cannabinoid launches planned for the first half of 2022; includes CBDV and THCVExpands...
Yumanity Reports Partial Clinical Hold by U.S. FDA on Multidose Clinical Trials for YTX-7739
BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development...
Vivos Therapeutics Announces 18X Increase in Sleep Apnea Diagnostic Testing By Vivos Dentists Using SleepImage Technology
Vivos Also Announces Improved Pricing Agreement With SleepImage Dentists and Patients Report Exceptional User Experience with SleepImage Home Sleep Test...
Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression
London, UK and New York, US, 19 January 2022 COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated...
BioXcel Therapeutics Appoints Matt Wiley Chief Commercial Officer
NEW HAVEN, Conn., Jan. 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study
VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB:...
Recro Appoints Eduardo Uribe as Head of Quality for Recro San Diego
Latest Appointment Continues Build-Out of Leadership Team for San Diego OperationsSAN DIEGO and GAINESVILLE, Ga., Jan. 19, 2022 (GLOBE NEWSWIRE)...
ADMA Biologics Announces Record Preliminary Fourth Quarter and Full Year 2021 Revenues and Provides 2022 Business Update
Fourth Quarter 2021 Preliminary Unaudited Total Revenues of Approximately $26 Million, the Highest Quarterly Revenue for the Company Since Inception...
Toronto’s Lead Agency for Child & Youth Mental Health enters into a 5-year agreement with VitalHub to license TREAT for their Integrated Client Information and Care Coordination Solution
TORONTO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company”) (TSX: VHI) is pleased to announce the 5-year licensing...
PetVivo Holdings to Present at Emerging Growth Conference on January 19, 2022
PetVivo Holdings, Inc. John Lai PetVivo Holdings, Inc. invites individual and institutional investors as well as advisors and analysts, to...
